Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-017547
Filing Date
2022-11-14
Accepted
2022-11-14 06:54:12
Documents
107
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q jagx-20220930x10q.htm   iXBRL 10-Q 3035939
2 EX-31.1 jagx-20220930xex31d1.htm EX-31.1 11021
3 EX-31.2 jagx-20220930xex31d2.htm EX-31.2 11020
4 EX-32.1 jagx-20220930xex32d1.htm EX-32.1 6967
5 EX-32.2 jagx-20220930xex32d2.htm EX-32.2 6942
  Complete submission text file 0001558370-22-017547.txt   13734017

Data Files

Seq Description Document Type Size
6 EX-101.SCH jagx-20220930.xsd EX-101.SCH 119923
7 EX-101.CAL jagx-20220930_cal.xml EX-101.CAL 73614
8 EX-101.DEF jagx-20220930_def.xml EX-101.DEF 578900
9 EX-101.LAB jagx-20220930_lab.xml EX-101.LAB 845518
10 EX-101.PRE jagx-20220930_pre.xml EX-101.PRE 755577
101 EXTRACTED XBRL INSTANCE DOCUMENT jagx-20220930x10q_htm.xml XML 2395580
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36714 | Film No.: 221379996
SIC: 2834 Pharmaceutical Preparations